🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Read the editorial from Editor-in-Chief Dan Nomura, PhD, to learn more about his vision for the future of Molecular Cancer Therapeutics: doi.org/10.1158/1535-7…

Read the latest editors' picks: aacrjournals.org/pages/editors-… Stay up to date with the AACR journals by signing up for alerts: aacrjournals.org/pages/alerts

Assistant Editor Danielle Large, PhD, is in Chicago attending the 2025 ASCO Annual Meeting and would love to hear about your research. Connect with her to discuss your work and learn about submitting to the journal. #ASCO25

Have a new drug candidate whose structure has not been reported in the literature? Submit your study as a First Disclosure article, which extends to all drug categories—including cell and gene therapies as well as novel combination approaches. brnw.ch/21wT5Jo

Have you read the latest Editors' Pick? Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity aacrjournals.org/mct/article/24…

Check out highlights from the June issue: brnw.ch/21wTbkG

#FirstDisclosure Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC: brnw.ch/21wTdhG

#FirstDisclosure Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile: brnw.ch/21wTgzl

Have you read the editorial from our new Editor-in-Chief Dan Nomura, PhD? Don't miss it to learn more about his vision for the journal: doi.org/10.1158/1535-7…

Congratulations to Analisa DiFeo, PhD, and colleagues, recipients of the 2025 Molecular Cancer Therapeutics Award for Outstanding Journal Article. Learn more and read the article: brnw.ch/21wTivI Analisa DiFeo Michigan Medicine Michigan Pathology U-M Rogel Cancer Center

Read "Towards Degrader-Antibody Conjugates," a collection focused on the preclinical to early clinical development of novel #ADCs and #proteindegraders: aacrjournals.org/collection/106…

Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer brnw.ch/21wTlGf

#OnlineFirst: Anti-HER2, High-DAR Antibody Fragment Drug Conjugates (FDC) with a Glucuronide-based MMAE Linker-Payload Demonstrates Superior Efficacy over IgG-based ADCs. doi.org/10.1158/1535-7… #HER2 #FirstDisclosure

Commentary: Three Articles from the NCI’s Preclinical Chemoradiotherapy Testing Consortium brnw.ch/21wTnqI

Sign up to receive alerts directly to your inbox to keep up with the latest published issues: aacrjournals.org/pages/alerts

Molecular Cancer Therapeutics is the central hub for #FirstDisclosures in cancer. Catch up on the latest articles: brnw.ch/21wTrgO

Olaparib and Radiotherapy Induce Type I Interferon– and CD8+ T Cell–Dependent Sensitization to Immunotherapy in Pancreatic Cancer: brnw.ch/21wTsSt

New in Small Molecule Therapeutics: DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits brnw.ch/21wTv23

Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor–Positive Triple-Negative Breast Cancer by Inhibiting c-MYC–mediated Tumorigenesis Available: brnw.ch/21wTwSw